Pipeline

TechnoPhage currently holds a well-balanced and diversified product portfolio addressing key therapeutic and non-therapeutic areas while simultaneously being agile in meeting the challenges of the rapidly evolving pharmaceutical industry.

Therapeutic products

Infection

DiscoveryPreclinicalIND/CTAPhase IPhase IIPhase III

  • Chronic ulcers (TP-102) 64.5% 64.5%
  • Respiratory infection (TP-122) 49.8% 49.8%
  • Urinary tract infection (TP-164) 15.8% 15.8%
  • COVID-19 (TA-201) 32.5% 32.5%

Neuroscience

DiscoveryPreclinicalIND/CTAPhase IPhase IIPhase III

  • Alzheimer’s disease (TA-111) 27.2% 27.2%
  • Parkinson’s disease (TZ-113) 41.5% 41.5%
  • Spinal cord injury (TZ-161) 41.5% 41.5%
  • Undisclosed indication (TA-191) 5% 5%

Ophthalmology

DiscoveryPreclinicalIND/CTAPhase IPhase IIPhase III

  • Age macular degeneration (TA-111/16) 27.2% 27.2%
  • Undisclosed indication (TA-182) 12.5% 12.5%

Non-therapeutic products

Biomarkers

DiscoveryPreclinicalClinical

  • Biomarker (TA-111C) 23.5% 23.5%
  • Biomarker (TA-211) 8.5% 8.5%

Others

DiscoveryPreclinical

  • Novel food (C1) 60% 60%

Therapeutic products

Non-therapeutic products